RNAimmune Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $27M

  • Investors
  • 7

RNAimmune General Information

Description

Developer of messenger ribonucleic acid-based therapeutics and vaccines designed to tackle indications in cancer, infectious, and rare diseases. The company leverages mRNA as a data carrier to instruct the human body to build responsive mechanisms against serious infectious diseases, enabling the medical industry to address unmet needs in the treatment of viral infections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 20511 Seneca Meadows Parkway
  • Suite 260
  • MD 20876
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 20511 Seneca Meadows Parkway
  • Suite 260
  • MD 20876
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RNAimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 29-Mar-2022 $27M Completed Clinical Trials - Phase 1
1. Seed Round 21-Apr-2021 Completed Clinical Trials - Phase 1
To view RNAimmune’s complete valuation and funding history, request access »

RNAimmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view RNAimmune’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

RNAimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of messenger ribonucleic acid-based therapeutics and vaccines designed to tackle indications in cancer, infect
Drug Discovery
MD
11 As of 2025

Natick, MA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RNAimmune Competitors (83)

One of RNAimmune’s 83 competitors is Allorion Therapeutics, a Venture Capital-Backed company based in Natick, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allorion Therapeutics Venture Capital-Backed Natick, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
etherna Formerly VC-backed Niel, Belgium
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Cognition Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 83 competitors. Get the full list »

RNAimmune Patents

RNAimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025081002-A1 Ionizable lipids for the delivery of nucleic acids Inactive 11-Oct-2023
WO-2025023949-A1 Combination ras mrna cancer therapy Inactive 21-Jul-2023
WO-2025024336-A1 Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines Inactive 21-Jul-2023
WO-2025024338-A2 Ras mrna cancer vaccines and compositions and methods thereof Inactive 21-Jul-2023
WO-2025024338-A3 Ras mrna cancer vaccines and compositions and methods thereof Inactive 21-Jul-2023 A61P35/00
To view RNAimmune’s complete patent history, request access »

RNAimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RNAimmune Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Shenzhen Qianhai Rotating Stone Fund Management Growth/Expansion Minority
High Forest Venture Capital Minority
Hong Kong Hongrun Venture Capital Minority
Shanghai Walga Biotechnology Corporation Minority
Sirnaomics Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

RNAimmune FAQs

  • When was RNAimmune founded?

    RNAimmune was founded in 2020.

  • Where is RNAimmune headquartered?

    RNAimmune is headquartered in MD.

  • What is the size of RNAimmune?

    RNAimmune has 11 total employees.

  • What industry is RNAimmune in?

    RNAimmune’s primary industry is Drug Discovery.

  • Is RNAimmune a private or public company?

    RNAimmune is a Private company.

  • What is the current valuation of RNAimmune?

    The current valuation of RNAimmune is .

  • What is RNAimmune’s current revenue?

    The current revenue for RNAimmune is .

  • How much funding has RNAimmune raised over time?

    RNAimmune has raised $37M.

  • Who are RNAimmune’s investors?

    Shenzhen Qianhai Rotating Stone Fund Management, High Forest, Hong Kong Hongrun, Shanghai Walga Biotechnology, and Sirnaomics are 5 of 7 investors who have invested in RNAimmune.

  • Who are RNAimmune’s competitors?

    Allorion Therapeutics, Inovio Pharmaceuticals, etherna, Sangamo Therapeutics, and Cognition Therapeutics are some of the 83 competitors of RNAimmune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process